GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » Piotroski F-Score

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Piotroski F-Score : 6 (As of May. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Amphastar Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Amphastar Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Amphastar Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

AMPH' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Amphastar Pharmaceuticals was 8. The lowest was 2. And the median was 6.


Amphastar Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Amphastar Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Piotroski F-Score Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 5.00 7.00 7.00 6.00

Amphastar Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 7.00 6.00 6.00 6.00

Competitive Comparison of Amphastar Pharmaceuticals's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 26.124 + 49.222 + 36.167 + 43.177 = $154.7 Mil.
Cash Flow from Operations was 54.923 + 64.334 + 23.864 + 55.291 = $198.4 Mil.
Revenue was 145.712 + 180.556 + 178.105 + 171.836 = $676.2 Mil.
Gross Profit was 72.738 + 108.403 + 96.14 + 90.1 = $367.4 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(773.656 + 1378.266 + 1544.633 + 1512.912 + 1574.317) / 5 = $1356.7568 Mil.
Total Assets at the begining of this year (Mar23) was $773.7 Mil.
Long-Term Debt & Capital Lease Obligation was $622.7 Mil.
Total Current Assets was $555.1 Mil.
Total Current Liabilities was $255.2 Mil.
Net Income was 17.346 + 15.874 + 33.913 + 26.032 = $93.2 Mil.

Revenue was 123.467 + 120.129 + 135.023 + 140.022 = $518.6 Mil.
Gross Profit was 63.356 + 58.51 + 71.168 + 73.84 = $266.9 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(716.238 + 723.719 + 726.695 + 741.987 + 773.656) / 5 = $736.459 Mil.
Total Assets at the begining of last year (Mar22) was $716.2 Mil.
Long-Term Debt & Capital Lease Obligation was $96.9 Mil.
Total Current Assets was $407.7 Mil.
Total Current Liabilities was $105.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Amphastar Pharmaceuticals's current Net Income (TTM) was 154.7. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Amphastar Pharmaceuticals's current Cash Flow from Operations (TTM) was 198.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=154.69/773.656
=0.19994675

ROA (Last Year)=Net Income/Total Assets (Mar22)
=93.165/716.238
=0.13007548

Amphastar Pharmaceuticals's return on assets of this year was 0.19994675. Amphastar Pharmaceuticals's return on assets of last year was 0.13007548. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Amphastar Pharmaceuticals's current Net Income (TTM) was 154.7. Amphastar Pharmaceuticals's current Cash Flow from Operations (TTM) was 198.4. ==> 198.4 > 154.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=622.745/1356.7568
=0.4589953

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=96.866/736.459
=0.13152939

Amphastar Pharmaceuticals's gearing of this year was 0.4589953. Amphastar Pharmaceuticals's gearing of last year was 0.13152939. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=555.078/255.169
=2.17533478

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=407.67/105.635
=3.85923226

Amphastar Pharmaceuticals's current ratio of this year was 2.17533478. Amphastar Pharmaceuticals's current ratio of last year was 3.85923226. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Amphastar Pharmaceuticals's number of shares in issue this year was 53.013. Amphastar Pharmaceuticals's number of shares in issue last year was 51.97. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=367.381/676.209
=0.54329505

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=266.874/518.641
=0.51456402

Amphastar Pharmaceuticals's gross margin of this year was 0.54329505. Amphastar Pharmaceuticals's gross margin of last year was 0.51456402. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=676.209/773.656
=0.8740435

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=518.641/716.238
=0.72411824

Amphastar Pharmaceuticals's asset turnover of this year was 0.8740435. Amphastar Pharmaceuticals's asset turnover of last year was 0.72411824. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Amphastar Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Amphastar Pharmaceuticals  (NAS:AMPH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Amphastar Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Executives
Mary Z. Luo director, 10 percent owner, officer: COO and Chief Scientist 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou officer: EVP, Production C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins director
William J Peters officer: CFO, SVP & Treasurer C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi officer: SVP Corp Admin Center C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff director
Gayle Deflin director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst officer: EVP, QA & Regulatory Affairs 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee director 13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang director, 10 percent owner, officer: CEO & Chief Scientific Officer 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris director C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell director, officer: President 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc. 10 percent owner 13760 MAGNOLIA AVENUE, CHINO CA 91710